Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amlodipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 2/20 | 1.00 |
| ▸ | KCNK2 | O95069 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amlodipine SCHEMBL912531 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Levamlodipine SCHEMBL30994756 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL7174865 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL1816641 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL26478 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Levamlodipine SCHEMBL41283 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| SCHEMBL13097922 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL29664887 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| SCHEMBL29599419 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL6666635 | 0.99 | TBXA2R (0.98) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3708172-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ADVERSE DRUG REACTIONS BY STATIN | UNIV YONSEI IACF (KR) | 2025-09-10 | — | — | EP | claimed |
| EP-3960158-B1 | AMLODIPINE FORMULATIONS | SILVERGATE PHARMACEUTICALS INC (US) | 2025-05-21 | — | — | EP | claimed |
| EP-3658140-B1 | COMBINATIONS OF APROCITENTAN WITH FURTHER ACTIVE INGREDIENTS FOR THE TREATMENT OF RESISTANT HYPERTENSION | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-05-21 | — | — | EP | claimed |
| EP-3801460-B1 | TOPICAL AMLODIPINE SALTS FOR THE TREATMENT OF ANORECTAL DISEASES | TAVANTA THERAPEUTICS HUNGARY INCORPORATED (HU) | 2025-03-12 | — | — | EP | claimed |
| CN-119345157-A | Preparation method and application of transdermal preparation membrane capable of selectively penetrating excellent enantiomer | 中北大学 | 2025-01-24 | — | — | CN | claimed |
| EP-4230162-B1 | CHEMICAL ABLATION FORMULATIONS FOR VARIOUS DISEASES | NEUROTRONIC INC (US) | 2024-10-09 | — | — | EP | claimed |
| EP-3932398-B1 | PHARMACEUTICAL COMPOSITION OF SINGLE DOSAGE FORM FOR TREATING OR PREVENTING HYPERTENSION AND HYPERLIPIDEMIA | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2024-05-22 | — | — | EP | claimed |
| EP-4101454-B1 | COMPOSITIONS FOR USE IN THE TREATMENT OF HYPERTENSION | THE GEORGE INST FOR GLOBAL HEALTH (AU) | 2024-04-10 | — | — | EP | claimed |
| EP-3737676-B1 | ACETAL COMPOUNDS AND THERAPEUTIC USES THEREOF | LIGAND PHARM INC (US) | 2024-03-06 | — | — | EP | claimed |
| EP-3876912-B1 | MEDICAMENTS CONTAINING RIBOFLAVIN EXHIBITING IMPROVED FLOWABILITY | DSM IP ASSETS BV (NL) | 2023-04-19 | — | — | EP | claimed |
| EP-3573620-B1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION | THE GEORGE INST FOR GLOBAL HEALTH (AU) | 2022-12-14 | — | — | EP | claimed |
| EP-3236950-B1 | PHARMACEUTICAL COMPOSITION COMPRISING CANDESARTAN OR PHARMACEUTICALLY ACCEPTABLE SALTS OR ESTERS THEREOF AND AMLODIPINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | KRKA D D NOVO MESTO (SI) | 2022-11-23 | — | — | EP | claimed |
| WO-2026057546-A1 | PHARMACEUTICAL COMPOSITION COMPRISING COMBINATION OF AMLODIPINE, RAMIPRIL AND ROSUVASTATIN | ADAMED PHARMA S.A. (PL) | 2026-03-19 | — | — | WO | disclosed |
| WO-2026057546-A1 | PHARMACEUTICAL COMPOSITION COMPRISING COMBINATION OF AMLODIPINE, RAMIPRIL AND ROSUVASTATIN | ADAMED PHARMA S.A. (PL) | 2026-03-19 | — | — | WO | disclosed |
| EP-4710920-A1 | PHARMACEUTICAL COMPOSITION COMPRISING COMBINATION OF AMLODIPINE, RAMIPRIL AND ROSUVASTATIN | Adamed Pharma S.A. (PL) | 2026-03-18 | — | — | EP | disclosed |
| EP-4588475-A4 | NEBIVOLOL AND AMLODIPINE COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI YONSUN BIOTECHNOLOGY CO LTD (CN) | 2026-02-25 | — | — | EP | disclosed |
| EP-3773574-A4 | AMLODIPINE FORMULATIONS | Silvergate Pharmaceuticals, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| EP-3960158-A1 | AMLODIPINE FORMULATIONS | Silvergate Pharmaceuticals, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| WO-2022033459-A1 | USE OF DOUBLE NON-ONCOLOGY DRUG IN PREPARATION OF PHARMACEUTICAL COMPOSITION FOR TREATING CANCERS | 萧乃文 | 2022-02-17 | — | — | WO | disclosed |
| WO-2022035558-A1 | FORMULATIONS AND METHODS OF TREATING COVID-19 AND PREVENTING INFECTION WITH SARS-CoV-2 | PRENDERGAST PATRICK (AU) | 2022-02-17 | — | — | WO | disclosed |